Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8671037 | 0.94 | EHMT1 (0.74) | EHMT1ADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL8671033 | 0.94 | EHMT1 (0.74) | EHMT1ADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL29936475 | 0.94 | EHMT1 (0.74) | EHMT1ADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL8328542 | 0.93 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL1637468 | 0.93 | EHMT1 (0.76) | EHMT1ADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL9231760 | 0.93 | EHMT1 (0.76) | EHMT1ADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL1920531 | 0.92 | EHMT1 (0.74) | EHMT1ADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL10865966 | 0.92 | EHMT1 (0.74) | EHMT1ADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL3698839 | 0.91 | ADORA3 (0.72) | EHMT1ADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL873362 | 0.91 | ADORA3 (0.72) | EHMT1ADORA1SMN1; SMN2ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994023723-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE PROMOTION OF WOUND HEALING | NEW YORK UNIVERSITY (US) | 1994-10-27 | — | — | WO | claimed |
| US-20240229036-A9 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240132893-A1 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| EP-4299743-A1 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC Laboratories Co., Ltd. (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-20230272403-A1 | ANTISENSE OLIGONUCLEOTIDE INDUCING EXON SKIPPING OF ANGIOTENSIN CONVERTING ENZYME 2 GENE | KNC LABORATORIES CO., LTD. (JP) | 2023-08-31 | — | — | US | disclosed |
| EP-4201484-A1 | ANTISENSE NUCLEIC ACID INDUCING EXON SKIPPING OF ANGIOTENSIN CONVERTING ENZYME 2 GENE | KNC Laboratories Co., Ltd. (JP) | 2023-06-28 | — | — | EP | disclosed |
| EP-3146970-B1 | NUCLEIC ACID DRUG FOR INDUCING SKIPPING OF VARIANT EXON OF CD44 GENE AND INCREASING EXPRESSION OF NORMAL TYPE CD44 MRNA | KNC LABORATORIES CO LTD (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220220478-A1 | NUCLEIC ACID DRUG SUPPRESSING PRODUCTION OF MYOSTATIN GENE MRNA | KNC LABORATORIES CO., LTD. (JP) | 2022-07-14 | — | — | US | disclosed |
| EP-3995153-A1 | NUCLEIC ACID DRUG SUPPRESSING PRODUCTION OF MYOSTATIN GENE MRNA | KNC Laboratories Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-2364086-B1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8575127-B2 | Antithrombotic diadenosine tetraphosphates and related analogs | GLSYNTHESIS INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110257252-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-1994023723-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE PROMOTION OF WOUND HEALING | NEW YORK UNIVERSITY (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | G6PC1, GAA, GBA3 | EHMT1 4605/4885ADORA1 2515/4885SMN1; SMN2 298/4885 |
| US-20220220478-A1 | NUCLEIC ACID DRUG SUPPRESSING PRODUCTION OF MYOSTATIN GENE MRNA | MYOF, MSTN, MTPN | EHMT1 2923/4885ADORA1 2537/4885SMN1; SMN2 65/4885 |
| US-20110257252-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GP6, P2RY6, PFKP | EHMT1 2128/4885ADORA1 79/4885SMN1; SMN2 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.